Pharmacovigilance in older adults – New podcast episode

In focus / 29 October 2024

Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?


Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfizer discusses what makes this patient group so vulnerable to adverse drug reactions, how poor representation and using age alone to define older adults exacerbates this problem, and suggests ways forward in monitoring drug safety in older patients.

Related Articles

How diclofenac drove vultures to the brink and unleashed a rabies crisis

Pharmacovigilance as a key tool in the One Health approach to AMR

Orphan Drugs: Hope for rare disease communities

You may also like

Orphan Drugs: Hope for rare disease communities

Orphan drug monitoring emerges as a critical lifeline for rare diseases, offering hope to patients with uncommon medical conditions.

14 April 2025

Pharmacovigilance as a key tool in the One Health approach to AMR

The One Health approach aims to combat resistant organisms spreading between humans, animals and environments, safeguarding antimicrobials for the future.

21 May 2025

How diclofenac drove vultures to the brink and unleashed a rabies crisis

How one unusual crisis highlights the need to more effectively integrate the One Health approach and ecopharmacovigilance into pharmaceutical monitoring and legislation.

20 August 2025